Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

October 1, 2020 3:00 PM - 4:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/1/2020 3:00:20 PM 10/1/2020 4:00:20 PM Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

Join us for an informative discussion on how COVID-19 has affected patient access to diagnoses, care, and innovative therapies. We’ve assembled an expert panel that will explore these important issues from an oncology perspective.  Our forum - moderated by Robert K. Coughlin, President & CEO of MassBio - will feature the following speakers:

  • Dr. Meghan Mooradian, MD, Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
  • Kirsten Sloan, Managing Director, Policy, American Cancer Society’s Cancer Action Network (ACS CAN)
  • Michelle Carrillo, Director, Advocacy Relations-Oncology, Amgen


The COVID-19 pandemic has had a profound, direct impact on Massachusetts, with over 121,000 total cases-to-date. However, as response and recovery continue, the ripple effects reveal a much broader public health impact. Our health care system has been shaken to its core, perhaps none more than the area of cancer care.

An American Cancer Society Cancer Action Network (ACS CAN) survey of cancer patients and survivors focused on COVID-19 effects uncovered that of those in active treatment, 79% reported delays to their health care. What does the patient’s path to diagnosis and treatment look like? Has cancer care adapted to meet these challenges? How is Massachusetts uniquely positioned to meet the moment? Our panel of experts will address these questions and more from their patient, oncologist, and innovator perspectives.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.



This event is supported by Amgen

 Webinar, click "live-stream" button to view
President & CEO, MassBio
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.

Brought to you by